| Literature DB >> 35055128 |
Michele Spiniello1,2, Mark Scalf3, Amelia Casamassimi1, Ciro Abbondanza1, Lloyd M Smith3.
Abstract
RNA-binding proteins are crucial to the function of coding and non-coding RNAs. The disruption of RNA-protein interactions is involved in many different pathological states. Several computational and experimental strategies have been developed to identify protein binders of selected RNA molecules. Amongst these, 'in cell' hybridization methods represent the gold standard in the field because they are designed to reveal the proteins bound to specific RNAs in a cellular context. Here, we compare the technical features of different 'in cell' hybridization approaches with a focus on their advantages, limitations, and current and potential future applications.Entities:
Keywords: RNA molecules; RNA–protein interactions; ‘in cell’ hybridization methods
Mesh:
Substances:
Year: 2022 PMID: 35055128 PMCID: PMC8779001 DOI: 10.3390/ijms23020942
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Experimental conditions used in ‘in cell’ hybridization methods to identify proteins associated to selected RNAs.
| PROCEDURE | CHART-MS [ | ChIRP-MS | RAP-MS | PAIR | HyPR-MS |
|---|---|---|---|---|---|
| Type, cell amount used and target RNA studied | MCF-7 and BJ cells (108 cells) Neat lncRNA Malat-001 lncRNA | HeLa S3 cells U1 snRNA (~1 × 106 cpc) U2 snRNA 7 SK snRNA (2 × 105 cpc) Xist lncRNA (<2000 cpc) A-repeat mutant Xist | - Wild-type V6.5 ES cells (2–8 × 108 cells) U1 snRNA 18S rRNA pSM33 cells (2–8 × 108 cells) Xist lncRNA | Cortical cells (1–5 × 104) | HIV-1 infected Jurkat cells (5–7.5 × 107 cells)
unspliced full length HIV-1 RNA HIV-1 RNA splice variants Neat lncRNA (1000 cpc) Norad lncRNA (380 cpc) Malat-001 lncRNA (3800 cpc) C-Myc mRNA (60 cpc) |
| Controls | Lysate | Xist lncRNA capture: Lysate U1 snRNA U2 snRNA 7 SK snRNA Non-targeting probe Samples RNase treated | - Xist lncRNA capture: Xist capture in cells not expressing Xist Xist capture in cells not crosslinked 45 pre-ribosomal RNA |
GluR2mRNA Lysate No irradiation No PNA No irradiation, no PNA |
Lysate Poly(dT) Scrambled |
| Crosslinking | 1% formaldehyde for 10 min on cells and 3% formaldehyde for 30 min on nuclei | 3% formaldehyde for 30 min | UV irradiation | UV irradiation of Bpa, | 1% formaldehyde for 10 min |
| Solubilization | Sonication; 3 kbp is median size | Sonication; 100–500 bp is | Sonication and DNAse digestion;100–300 bp is the size of chromatin fragments length | Sonication; About 6 kbp is the median size of chromatin fragments | |
| Probes features | 25 nt DNA biotinylated at 3′ | 20 nt DNA biotinylated at 3′ | 90 nt DNA biotinylated at 3′ | PNA coupled to a CPP and to a Bpa | Hybridization part of 20–30 nt DNA biotinylated at 3′ and toehold part of 8 nt DNA |
| Hybridization | 2 COs per target each one used | 43 COs per Xist lncRNA | 142 COs per Xist lncRNA (probes | 3 COs (PNA) per target each one used for a 25 mM Hepes pH 7.4, 0.75 mM Na2HPO4, 70 mM NaCl 90 min in cell culture at 37–42 °C | 2–3 COs per target per experiment |
| Beads coupling | Overnight, RT | 37 °C for 30 min | 67 °C for 30 min | 1 h at RT (Biotinylated sense DNA coupled to the beads) | 37 °C for 1 h |
| Washing | 250 mM NaCl, 0.22% SDS, 10 mM Hepes pH 7.5 | 300 mM NaCl and 30 mM Sodium citrate | 4 M urea, 500 mM LiCl, 10 mM Tris pH 7.5, 0.2% SDS | 25 mM Hepes, pH 7.4, 0.1% Triton X-100, | 375 mM LiCl, 50 mM Tris pH 7.5, 0.2% LiDS, |
| Elution | RNase-H digestion | Biotin-elution at RT for 20 min and at 65 °C | Benzonase nonspecific RNA/DNA | 50 °C for 20 min | Toehold mediated release |
Bpa (p-benzoylphenylalanine); PNA (peptide nucleic acid); and CPP cell penetrating peptide.
Figure 1Schematic representation of in cell hybridization-based methods workflow [37,38,39,40,42,43,44,45,46].
Comparison amongst in cell hybridization methods based on setting-up features that impact their wide-spread diffusion.
| CHART-MS | ChIRP-MS | RAP-MS | PAIR | HyPR-MS | ||
|---|---|---|---|---|---|---|
| SETTING-UP | Cost saving | • | •• | •• | • | ••• |
| Time saving | • | ••• | ••• | • | •• | |
| Technical | ••• | •• | •• | ••• | •• | |
| Characterization level | •• | ••• | ••• | •• | •• |
One circle represents least desirable, two circles represent average, and three circles represent most desirable.
Comparison amongst in cell hybridization methods based on procedure features that impact their wide-spread diffusion.
| CHART-MS | ChIRP-MS | RAP-MS | PAIR | HyPR-MS | ||
|---|---|---|---|---|---|---|
| PROCEDURE | Cost | •• | •• | •• | •• | ••• |
| Time saving | •• | •• | •• | •• | ••• | |
| Versatility | •• | • | • | •• | ••• | |
| Purification | • | ••• | ••• | •• | ||
| Purification | 58S RNA enrichment using NEAT and MALAT COs (<1%) ## | No GAPDH detected using XIST Cos ## | 18S RNA enrichment using XIST COs | UFL HIV-1 RNA (60-fold) # MALAT, NEAT, NORAD lncRNAs (10–110-fold) # MALAT, NEAT, NORAD DNA capture (<0.1%) C-Myc mRNA (45-fold) # C-Myc DNA capture (<0.03%) |
One circle represents least desirable, two circles represent average, and three circles represent most desirable. * Purification efficiency is calculated by measuring the amount of RNA target captured compared to the amount of total target in the initial lysate. ** Purification efficiency is calculated by measuring the amount of each HIV splice variant class in the lysate before (pre-lys) and after (post-lys) the capture. Purification specificity is calculated by measuring the amount of a given RNA target captured (using the complementary COs), divided by the amount of that same RNA captured using the COs for different RNAs or for the scrambled CO (#) or measuring the amount of off-target RNA captured using the CO for a specific target (##). In the first case (#) higher values are associated with a greater specificity and vice versa in the second solution (##).
RNA protein interactome validation strategies in ‘in cell’ hybridization methods [37,38,39,40,41,42,43,45,46].
| CHART-MS | ChIRP-MS | RAP-MS | PAIR | HyPR-MS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STUDIED RNA |
|
|
|
|
|
| 18S |
|
|
|
|
|
| |||
| IDENTIFIED | 69 | 71 | 418 | 370 | 81 | 9 | 105 | 10 | 13 | 189 | 926 (CI) | 127 | 94 | 415 | 229 | |
| V | Previous known | 9/9 | 92 | 117/926 | 52 | 24 | 33 | 25 | ||||||||
| Interacting proteins ‘functionally’ linked to the related RNA | ~42 | ~41 | 143 | 143 | 13 | 98 | 9 | 13 | 89 | 633/926 | ~117 | ~66 | 145 | 209 | ||
| Direct validation | 2/69–2/71 | 1 | 3 | 8 | 2 | 8 | 84 (DI) | 2/127–2/94–2/415 | 2 | |||||||
US (Unspliced) (US); PS (Partially Spliced); CS (Completely Spliced); CI (Common Interactors); DI (Differential Interactors); WB (Western Blot); IP (Immunoprecipitation); IB (Immunoblot); KD (Knockdown); and FM (fluorescence microscopy).